Adipose-Derived Mesenchymal Stem Cell Lines for Stable Hepatic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hepatic disorders using adipose-derived mesenchymal stem cells (ASC) face variability in therapeutic effect due to donor quality and instability in supply, lacking a stable and effective therapeutic solution.
Innovation Solution
A method for producing a mesenchymal stem cell line (ASCL) from adipose tissue through differentiation and dedifferentiation of stromal vascular fraction cells using specific enzymes and culture conditions, ensuring stable supply and enhanced therapeutic efficacy for hepatic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adipose-derived mesenchymal stem cells (ASC) are used for treating hepatic disorders, then therapeutic effect is achieved, but the therapeutic effect varies largely due to donor quality and stable supply is difficult
Solution Approach 1:
The invention creates a cell line (ASCL) that copies the therapeutic properties of original ASC but can be produced indefinitely. The cell line is established by culturing and passaging ASC, creating a replicable model that eliminates donor variability while maintaining therapeutic efficacy for hepatic disorders
Solution Approach 2:
The invention changes the parameter of cell source from primary donor tissue to established cell line. This parameter change transforms the system from one dependent on donor characteristics to one with standardized, reproducible properties, ensuring consistent therapeutic effect across different treatments
2Reliability
If mesenchymal stem cells are used to treat hepatic disorders, then treatment efficacy is improved, but the quality of donor cells causes large variation in therapeutic effect
Solution Approach 1:
The invention creates a standardized cell line that replicates the therapeutic properties of ASC without donor variability. The cell line serves as a consistent copy that can be produced in large quantities with uniform characteristics, eliminating the problem of donor cell quality variation
Solution Approach 2:
The invention achieves homogeneity by establishing a cell line with standardized characteristics. All cells in the ASCL population have consistent properties regardless of original donor variations, ensuring uniform therapeutic effect across different treatment batches
Data Source
AI summary
An object of the present invention is to provide, for example, a therapeutic agent for hepatic disorders using a specific mesenchymal stem cell line derived from an adipose tissue (ASCL), the therapeutic agent being capable of being preserved and stably supplied and having a better therapeutic effect on hepatic disorders. A feature of the present invention is to use a mesenchymal stem cell line derived from an adipose tissue, the mesenchymal stem cell line having been produced by a production method comprising: (A) inducing differentiation of one or more cells selected from a stromal vascular fraction of a vertebrate animal adipose tissue comprising a mesenchymal stem cell, an adipose progenitor cell, and a stromal cell into a mature adipocyte; and (B) inducing dedifferentiation of the mature adipocyte obtained in step (A) to obtain a mesenchymal cell line derived from the vertebrate animal adipose tissue.